Trials / Completed
CompletedNCT01059903
Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body
Single-site, Open-label, Randomized, Cross-over Trial to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (4.5mg/10cm2) Comparing Two Different Formulations
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The major aim of this study is to investigate and compare the drug amount delivered to the body after sequential application of two Rotigotine patches of two different formulations
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rotigotine transdermal patch | Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2010-02-01
- Completion
- 2010-03-01
- First posted
- 2010-02-01
- Last updated
- 2012-05-22
- Results posted
- 2011-03-03
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01059903. Inclusion in this directory is not an endorsement.